{
  "fullName": "Stanley Prusiner",
  "slug": "stanley-prusiner",
  "title": "MD",
  "specialty": "Nobel Prize",
  "geography": {
    "country": "Global",
    "city": "Unknown",
    "region": "Unknown"
  },
  "status": "LIVING",
  "tier": "TITAN",
  "rankingScore": 28,
  "hIndex": 154,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Stanley Ben Prusiner is an American neurologist and biochemist. He is the director of the Institute for Neurodegenerative Diseases at the University of California, San Francisco (UCSF). Prusiner discovered prions, a class of infectious self-reproducing pathogens primarily or solely composed of protein, a scientific theory considered by many as a heretical idea when first proposed. He received the Albert Lasker Award for Basic Medical Research in 1994 and the Nobel Prize in Physiology or Medicine in 1997 for research on prion diseases developed by him and his team of experts beginning in the early 1970s.",
  "aiSummary": "Stanley Prusiner is a nobel prize specialist with an H-index of 154 at UCSFNeurology (Member). Has been published in Proceedings of the National Academy of Sciences, Science, Nature. Based in Unknown, Unknown, Global.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "UCSFNeurology"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "UCSFNeurology",
      "role": "Member",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Nobel Prize"
  ],
  "knowsAbout": [
    "Prion disease discovery"
  ],
  "citations": [
    {
      "title": "Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components.",
      "journal": "Neuron",
      "year": 2021,
      "citationCount": 0,
      "doi": "10.1016/j.neuron.2021.03.026",
      "pubmedId": "33848474",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/33848474/"
    },
    {
      "title": "Prions.",
      "journal": "Cold Spring Harb Perspect Biol",
      "year": 2011,
      "citationCount": 0,
      "doi": "10.1101/cshperspect.a006833",
      "pubmedId": "21421910",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/21421910/"
    },
    {
      "title": "α-Synuclein: Multiple System Atrophy Prions.",
      "journal": "Cold Spring Harb Perspect Med",
      "year": 2018,
      "citationCount": 0,
      "doi": "10.1101/cshperspect.a024588",
      "pubmedId": "28213437",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/28213437/"
    },
    {
      "title": "Expanding spectrum of prion diseases.",
      "journal": "Emerg Top Life Sci",
      "year": 2020,
      "citationCount": 0,
      "doi": "10.1042/ETLS20200037",
      "pubmedId": "32803268",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/32803268/"
    },
    {
      "title": "Bioassays and Inactivation of Prions.",
      "journal": "Cold Spring Harb Perspect Biol",
      "year": 2017,
      "citationCount": 0,
      "doi": "10.1101/cshperspect.a023499",
      "pubmedId": "28246183",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/28246183/"
    }
  ],
  "awards": [],
  "timeline": [],
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/commons/thumb/1/1f/Stanley_B._Prusiner_in_2024_%283x4_cropped%29.jpg/330px-Stanley_B._Prusiner_in_2024_%283x4_cropped%29.jpg",
  "openalexId": "https://openalex.org/A5066991343",
  "bio": "## Dr. Stanley Prusiner: A Biography\n\nDr. Stanley Prusiner's journey into the annals of medical history is a testament to intellectual tenacity, groundbreaking research, and the unwavering pursuit of scientific truth, even in the face of considerable skepticism. While the details of his private practice remain discreet, his legacy is firmly cemented through his revolutionary work on prions and the awarding of the Nobel Prize in Physiology or Medicine in 1997. This biography explores the trajectory of his remarkable career, highlighting his academic foundations, research breakthroughs, and the profound impact he has had on our understanding of infectious diseases.\n\n## 1. Early Life and Education\n\nBorn in Des Moines, Iowa, in 1942, Stanley Ben Prusiner's early life was marked by a fervent curiosity and a strong academic aptitude. The son of an architect and a homemaker, he demonstrated an early interest in science, nurtured by family discussions and personal exploration. His family's relocation to Cincinnati, Ohio, provided access to better educational opportunities, which he readily embraced.\n\nPrusiner's undergraduate studies were undertaken at the University of Pennsylvania, where he pursued a Bachelor of Science degree in chemistry. This period was crucial in shaping his scientific mindset, exposing him to the rigors of laboratory research and the importance of meticulous experimentation. He found particular fascination in the intricate workings of biological molecules, a passion that would later define his career.\n\nDriven by a desire to apply his scientific knowledge to the alleviation of human suffering, Prusiner matriculated at the University of Pennsylvania School of Medicine, earning his medical degree in 1968. His medical education was further honed through an internship at the University of California, San Francisco (UCSF), a leading center for medical research and innovation. During this time, he began to appreciate the complexities of neurological diseases, particularly those that defied conventional explanations.\n\nA pivotal moment in Prusiner's early career came during his service as a Lieutenant Commander in the United States Public Health Service at the National Institutes of Health (NIH) from 1969 to 1972. Assigned to the National Heart and Lung Institute, he investigated the metabolism of glutaminase in *E. coli*. Although seemingly unrelated to his later prion research, this experience provided invaluable training in biochemical techniques and the scientific method. It instilled in him the importance of rigorous experimentation and the ability to critically evaluate scientific data.\n\nReturning to UCSF in 1972, Prusiner embarked on a neurology residency, solidifying his clinical expertise in the diagnosis and management of neurological disorders. This period was marked by a growing frustration with the limited understanding of certain neurodegenerative diseases, particularly Creutzfeldt-Jakob disease (CJD), a rare and invariably fatal condition characterized by rapidly progressive dementia.\n\n## 2. Medical Philosophy\n\nDr. Prusiner's medical philosophy is rooted in a profound commitment to scientific rigor and a relentless pursuit of understanding the underlying mechanisms of disease. He is driven by the belief that effective treatment strategies can only be developed through a deep understanding of the molecular basis of pathology. This commitment to translational research, bridging the gap between basic science and clinical application, has been a hallmark of his career.\n\nHis approach to patient care is characterized by a meticulous attention to detail, a willingness to challenge conventional wisdom, and a strong emphasis on evidence-based medicine. While the specifics of his private practice are not publicly available, it is reasonable to infer that his patients would benefit from his encyclopedic knowledge of neurology and his innovative approach to diagnosis and treatment.\n\nPrusiner's innovative thinking is perhaps best exemplified by his conceptualization of prions as infectious agents. This idea, initially met with widespread skepticism, challenged the central dogma of molecular biology, which held that only nucleic acids (DNA or RNA) could transmit genetic information. His unwavering belief in his findings, despite the resistance from the scientific community, underscores his intellectual courage and his commitment to scientific truth.\n\nHis practice ethics are grounded in the principles of beneficence, non-maleficence, autonomy, and justice. He recognizes the importance of informed consent, patient confidentiality, and equitable access to medical care. While these principles are fundamental to all medical practitioners, Prusiner's dedication to translational research highlights his commitment to improving the lives of patients through scientific discovery.\n\n## 3. Key Procedures & Clinical Expertise\n\nWhile Dr. Prusiner's Nobel Prize was awarded for his groundbreaking research on prions, this research was inextricably linked to his clinical understanding of prion diseases. His expertise extended beyond the laboratory, encompassing the diagnosis and management of patients suffering from these devastating conditions.\n\nHis clinical expertise in neurology allowed him to identify the key features of prion diseases, such as CJD, Gerstmann-Sträussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI), and kuru. He meticulously documented the clinical presentations of these diseases, paying close attention to the neurological symptoms, cognitive decline, and neuropathological findings.\n\nHis understanding of the clinical manifestations of prion diseases was crucial in guiding his research efforts. He recognized that these diseases shared a common pathological feature: the accumulation of abnormal protein aggregates in the brain. This observation led him to hypothesize that these aggregates were the infectious agent, a radical idea that ultimately transformed our understanding of infectious diseases.\n\nThe technical skills and specialization that earned him the Nobel Prize were not procedures in the traditional surgical sense, but rather sophisticated biochemical and molecular biology techniques. These included:\n\n*   **Protein purification and characterization:** Prusiner developed innovative methods for purifying and characterizing the infectious agent responsible for prion diseases. This involved separating the infectious agent from brain tissue and determining its biochemical properties.\n*   **Antibody production and immunoassays:** He produced antibodies that specifically recognized the prion protein, allowing him to develop sensitive immunoassays for detecting the protein in biological samples.\n*   **Gene cloning and sequencing:** Prusiner and his team cloned and sequenced the gene encoding the prion protein, providing definitive evidence that the protein was encoded by the host genome.\n*   **Transgenic mouse models:** He developed transgenic mouse models that were susceptible to prion diseases, allowing him to study the pathogenesis of these diseases and to test potential therapies.\n\nThese techniques, while not directly involved in patient care, were essential for understanding the molecular basis of prion diseases and for developing diagnostic tools and potential therapies.\n\n## 4. Academic Contributions & Research\n\nDr. Prusiner's academic contributions are primarily focused on the discovery and characterization of prions, infectious agents composed entirely of protein. His research challenged conventional wisdom and revolutionized our understanding of infectious diseases.\n\nHis key publications, particularly those detailing the isolation and characterization of the prion protein, were initially met with skepticism. However, as his research progressed and his findings were replicated by other scientists, the prion hypothesis gained increasing acceptance. His seminal paper, \"Novel proteinaceous infectious particles cause scrapie,\" published in *Science* in 1982, marked a turning point in the field.\n\nHis research focus areas included:\n\n*   **The structure and function of the prion protein:** Prusiner and his team elucidated the structure of the prion protein and investigated its role in the pathogenesis of prion diseases.\n*   **The mechanism of prion replication:** They investigated how prions replicate themselves in the absence of nucleic acids, a process that remains a subject of intense investigation.\n*   **The development of diagnostic tests for prion diseases:** Prusiner developed sensitive and specific diagnostic tests for detecting prions in biological samples, which have been instrumental in preventing the spread of prion diseases through medical procedures.\n*   **The development of therapies for prion diseases:** While there are currently no effective therapies for prion diseases, Prusiner's research has laid the groundwork for the development of potential therapeutic strategies.\n\nHis research has had a profound impact on medical science, influencing fields as diverse as neurology, immunology, and cell biology. The discovery of prions has not only transformed our understanding of infectious diseases but has also provided insights into the pathogenesis of other neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, which also involve the accumulation of misfolded protein aggregates.\n\n## 5. Patient Impact & Community Work\n\nWhile the direct impact of Dr. Prusiner's private practice on individual patients remains largely undocumented, his research has had a significant and far-reaching impact on the lives of patients suffering from prion diseases and other neurodegenerative disorders.\n\nHis development of diagnostic tests for prion diseases has been instrumental in preventing the spread of these diseases through medical procedures, such as blood transfusions and organ transplantation. These tests have also allowed for earlier diagnosis of prion diseases, enabling patients and their families to make informed decisions about their care.\n\nHis research has also provided hope for the development of future therapies for prion diseases. While there are currently no effective treatments for these devastating conditions, Prusiner's work has identified potential therapeutic targets and has laid the groundwork for the development of novel therapeutic strategies.\n\nBeyond his direct contributions to patient care, Dr. Prusiner has also been actively involved in community outreach and education. He has lectured extensively on prion diseases and has worked to raise awareness of these conditions among the general public. He has also been a strong advocate for increased funding for research into neurodegenerative disorders.\n\nHis commitment to translating his scientific findings into tangible benefits for patients and the community underscores his dedication to improving the lives of those affected by neurological diseases.\n\n## 6. Legacy and Future Outlook\n\nDr. Stanley Prusiner's legacy is secure as the discoverer of prions and the recipient of the Nobel Prize in Physiology or Medicine. His groundbreaking research has not only transformed our understanding of infectious diseases but has also provided insights into the pathogenesis of other neurodegenerative disorders.\n\nHe stands as a towering figure in the medical community, respected for his intellectual rigor, his unwavering commitment to scientific truth, and his dedication to improving the lives of patients. His work has inspired countless scientists and clinicians to pursue innovative research aimed at understanding and treating neurological diseases.\n\nLooking to the future, Dr. Prusiner's research continues to explore the role of prions and other misfolded proteins in neurodegenerative disorders. He is actively involved in the development of novel diagnostic tools and therapeutic strategies for these conditions.\n\nHis legacy extends beyond his own research, serving as a testament to the power of scientific inquiry and the importance of challenging conventional wisdom. His work has paved the way for future discoveries in the field of neurodegenerative diseases and promises to have a lasting impact on the health and well-being of patients worldwide. He continues to inspire future generations of scientists to pursue bold and innovative research aimed at unraveling the mysteries of the human brain and developing effective treatments for neurological disorders.\n",
  "bioGenerated": true
}